Predictors of progression in Barrett's esophagus III: Baseline flow cytometric variables

American Journal of Gastroenterology

Volumn 96, Issue 11, 2001, Pages 3071-3083

  Rabinovitch, Peter S ^a   Longton, Gary ^c   Blount, Patrick L ^c   Levine, Douglas S ^b   Reid, Brian J ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ASTRAZENECA   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANEUPLOIDY; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CELL CYCLE S PHASE; ENDOSCOPIC BIOPSY; FLOW CYTOMETRY; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

BARRETT ESOPHAGUS; DISEASE PROGRESSION; DNA; FLOW CYTOMETRY; HUMANS; PLOIDIES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE;

EID: 0035180041     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)03823-0     Document Type: Article

References (70)

1. Rising incidence of adenocarcinoma of the esophagus and gastric cardia
2. Continuing climb in rates of esophageal adenocarcinoma: An update
3. Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction
4. Prevalence of metaplasia at the gastro-oesophageal junction
5. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States)
6. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus
7. The management of high-grade dysplasia and early cancer in Barrett's esophagus. A multidisciplinary problem
8. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients
9. Barrett's esophagus
10. Adenocarcinoma, and Barrett's esophagus. An overrated risk?
11. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus
12. Barrett's esophagus. Development of dysplasia and adenocarcinoma
13. Adenocarcinoma arising in Barrett's esophagus
14. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus
15. Barrett's esophagus: Prevalence and incidence of adenocarcinoma
16. The cost of surveillance for adenocarcinoma complicating Barrett's esophagus
17. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus
18. The incidence of adenocarcinoma in Barrett's esophagus: A prospective study of 170 patients followed 4.8 years
19. Surveillance for Barrett's esophagus: Are we saving lives?
20. Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk
21. Predictors of progression to cancer in Barrett's esophagus. Baseline histology and flow cytometry identify low and high risk patient subsets
22. Flow cytometric analysis of cellular DNA content in Barret's esophagus. A study of 66 cases
23. Cell proliferation in esophageal columnar epithelium (Barrett's esophagus)
24. Cell proliferation in three types of Barrett's epithelium
25. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression
26. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization
27. Consensus review of the clinical utility of DNA cytometry in bladder cancer. Report of the DNA Cytometry Consensus Conference
28. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Report of the DNA Cytometry Consensus Conference
29. Flow-cytometric, and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort
30. Progression to cancer in Barrett's esophagus is associated with genomic instability
31. Endoscopic diagnosis of esophageal neoplasms
32. Guidelines for implementation of clinical DNA cytometry
33. ROC methodology in radiologic imaging
34. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma
35. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus
36. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus
37. Mammalian G1 and G2 phase checkpoints
38. Barrett's esophagus: Does the incidence of adenocarcinoma matter?
39. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus
40. p53-mutant clones, and field effects in Barrett's esophagus
41. TP53 gene mutations, and p53 protein immunoreactivity in malignant, and premalignant Barrett's esophagus
42. Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia
43. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption
44. A p53-dependent mouse spindle checkpoint
45. Flow cytometry of human solid tumors
46. Flow-cytometric DNA analysis in primary breast carcinomas, and clinicopathological correlations
47. A model of DNA aneuploidization and evolution in colorectal cancer
48. The predictive value of flow cytometric information in the clinical management of stage O (Ta) bladder cancer
49. The value of morphometry and DNA flow cytometry in addition to classic prognosticators in superficial urinary bladder carcinoma
50. DNA profile and tumour progression in patients with superficial bladder tumours
51. Accessibility of DNA in situ to various fluorochrome: Relationship to chromatin changes during erythroid differentiation of friend leukemia cells
52. Autolysis is a potential source of false aneuploid peaks in flow cytometric DNA histograms
53. Model for the genetic evolution of human solid tumors
54. Karyotypic evolution of a human undifferentiated large cell carcinoma of the lung in tissue culture
55. Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice
56. Chemical induction of mitotic checkpoint override in mammalian cells results in aneuploidy following a transient tetraploid state
57. Chromosomal abnormalities in leukemia and lymphoma: Clinical and biological significance
58. Characterization of hematologic malignancies by flow cytometry
59. Evolution of neoplastic cell lineages in Barrett esophagus
60. Barrett's esophagus. The cytology of dysplasia in comparison to benign and malignant lesions
61. Low-grade dysplasia in Barrett's esophagus. Variable fate during long-term prosepective follow-up
62. Observer variation in the diagnosis of dysplasia in Barrett's esophagus
63. Observer variation in the diagnosis of dysplasia in Barrett's mucosa
64. Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquanitation and morphometry of features associated with proliferation and differentiation
65. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice
66. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus
67. The economic impact of the diagnosis of dysplasia in Barrett's esophagus